[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"daily-categories":3,"daily-reports:health:1":70},[4,8,12,15,18,22,25,28,31,35,38,41,44,48,51,54,58,62,66],{"slug":5,"name":6,"count":7},"all","综合",180,{"slug":9,"name":10,"count":11},"news","新闻",179,{"slug":13,"name":14,"count":7},"wool","羊毛",{"slug":16,"name":17,"count":7},"media","媒体",{"slug":19,"name":20,"count":21},"tv","电视",178,{"slug":23,"name":24,"count":21},"life","生活",{"slug":26,"name":27,"count":11},"community","社区",{"slug":29,"name":30,"count":11},"finance","财经",{"slug":32,"name":33,"count":34},"stock","股讯",140,{"slug":36,"name":37,"count":21},"sports","体育",{"slug":39,"name":40,"count":11},"technology","科技",{"slug":42,"name":43,"count":11},"design","设计",{"slug":45,"name":46,"count":47},"audiovideo","影音",176,{"slug":49,"name":50,"count":21},"game","游戏",{"slug":52,"name":53,"count":21},"health","健康",{"slug":55,"name":56,"count":57},"education","教育",66,{"slug":59,"name":60,"count":61},"futures","期货",65,{"slug":63,"name":64,"count":65},"ai","AI",59,{"slug":67,"name":68,"count":69},"sideline","副业",58,{"items":71,"page":107,"totalPages":224,"total":21},[72,91,109,125,142,157,171,184,197,210],{"id":73,"title":74,"summary":75,"category":52,"categoryName":53,"publishDate":76,"coverImage":77,"concepts":78,"aiPlatform":83,"aiModel":84,"model":85,"provider":86,"tokenUsage":87,"readMinutes":88,"heat":89,"markdown":90},3871,"健康领域双线升温：日常科普贴近民生 前沿技术落地加速","2026年6月20日健康领域热点呈现清晰双线特征：一端是全年龄段覆盖的日常健康科普，从慢病防治、儿童防护到老年健康、食品安全风险提示，紧密贴合民生日常；另一端是创新药与AI医疗的前沿进展密集落地，涵盖重磅交易、技术突破与监管新规。两类内容共同反映公众主动健康管理需求持续升温，前沿技术正加速从实验室走向产业，同时健康科普的权威性甄别值得关注。","2026-06-20","https:\u002F\u002Fr2-tgmeng.tgmeng.com\u002Ftgmeng-news\u002F1(178).jpg",[79,80,81,82],"日常健康科普","创新药动态","AI医疗落地","消费健康风险","NVIDIA","step-3.7-flash","stepfun-ai\u002Fstep-3.7-flash","糖果梦",29260,2,233,"",{"id":92,"title":93,"summary":94,"category":52,"categoryName":53,"publishDate":95,"coverImage":96,"concepts":97,"aiPlatform":103,"aiModel":104,"model":104,"provider":105,"tokenUsage":106,"readMinutes":107,"heat":108,"markdown":90},3852,"减重药与AI制药狂飙，创新药企出海迎高光时刻","2026年6月19日，医药健康领域呈现产业爆发与民生关切并行的态势。产业端，GLP-1减重药赛道扩容，司美格鲁肽适应症持续拓展，国产长效减重药密集申报，市场竞争白热化；AI制药在巨额融资与超级工厂概念下走向商业化深水区，但也伴随泡沫警示。细胞治疗领域，CAR-T疗法在新加坡获批及跨界应用标志中国创新药出海取得实质性突破。与此同时，医药集采常态化加剧行业洗牌，部分传统药企面临生存危机。公众端，夏季食品安全与脑科学前沿发现成为热议焦点，折射出健康意识的全面提升。","2026-06-19","https:\u002F\u002Fr2-tgmeng.tgmeng.com\u002Ftgmeng-news\u002F1(46).jpg",[98,99,100,101,102],"GLP-1减重药","AI制药","细胞治疗出海","集采洗牌","夏季健康警示","agnes-ai","agnes-2.0-flash","糖果",17530,1,285,{"id":110,"title":111,"summary":112,"category":52,"categoryName":53,"publishDate":113,"coverImage":114,"concepts":115,"aiPlatform":120,"aiModel":104,"model":104,"provider":121,"tokenUsage":122,"readMinutes":123,"heat":124,"markdown":90},3833,"国产创新药崛起与健康消费新图景","生物医药产业迎来双重变革：GLP-1减重赛道从价格战转向技术迭代，国产口服药物密集推进；AI制药进入兑现期，多个\"全球首个\"细胞治疗获FDA批准标志着中国从跟随走向引领。公众健康焦虑持续升温，慢性病患者管理需求激增，医保支付博弈决定创新药可及性。与此同时，行业合规趋严倒逼企业转型，季节性健康风险成为民生关注焦点。","2026-06-18","https:\u002F\u002Fr2-tgmeng.tgmeng.com\u002Ftgmeng-news\u002F1(205).jpg",[116,117,99,118,119],"国产创新药","减重赛道","健康消费","医药政策","Agnes AI","yfw",15766,5,440,{"id":126,"title":127,"summary":128,"category":52,"categoryName":53,"publishDate":129,"coverImage":130,"concepts":131,"aiPlatform":136,"aiModel":137,"model":137,"provider":138,"tokenUsage":139,"readMinutes":140,"heat":141,"markdown":90},3814,"创新药临床突破与AI生物制造融资共振","今日健康领域呈现科研突破与资本活跃的双主线。中国学者在Cell、Nature发表多项线粒体与免疫代谢机制研究成果，为卒中及代谢病治疗提供新靶点。同时，慢性乙肝功能性治愈、mRNA疫苗III期进展及GLP-1减重药数据披露，显示中国创新药全球竞争力提升。资本端，AI蛋白质设计领域迎来超亿美元融资潮，合成生物制造白皮书发布。此外，消费者端止汗针误用、泡药杨梅等健康警示频发，需加强科普与监管。","2026-06-17","https:\u002F\u002Fr2-tgmeng.tgmeng.com\u002Ftgmeng-news\u002F1(62).jpg",[132,133,134,135],"创新药进展","AI生物制造","基础医学研究","健康消费警示","Grok","grok-4.3","锟斤拷",19297,3,292,{"id":143,"title":144,"summary":145,"category":52,"categoryName":53,"publishDate":146,"coverImage":147,"concepts":148,"aiPlatform":152,"aiModel":153,"model":153,"provider":154,"tokenUsage":155,"readMinutes":88,"heat":156,"markdown":90},3795,"创新药加速兑现，医保与资本重塑医药生态","今天健康领域的核心主线并不在单一疾病或单个产品，而是医药产业全链条同时升温：创新药与新适应症密集获批，AI制药、基因编辑等平台技术继续制造想象空间；与此同时，医保限适应症、集采接续、基金监管和互联网医院明码标价强化支付约束。资本市场仍在追逐中国创新药，但合规、商业化和真实可及性正在成为更关键的检验标准。","2026-06-16","https:\u002F\u002Fr2-tgmeng.tgmeng.com\u002Ftgmeng-news\u002F1(139).jpg",[149,150,99,151,118],"创新药","医保控费","医药资本","Unity2","gpt-5.5","Unity2中转站",35274,304,{"id":158,"title":159,"summary":160,"category":52,"categoryName":53,"publishDate":161,"coverImage":162,"concepts":163,"aiPlatform":152,"aiModel":153,"model":153,"provider":154,"tokenUsage":169,"readMinutes":140,"heat":170,"markdown":90},3776,"创新药出海承压，前沿疗法与减重药升温","6月15日健康领域的核心热度集中在医药产业：创新药出海、License-out监管、药企融资上市与回购增持共同构成硬主线；GLP-1及下一代减重药继续放大商业化想象；基因编辑、体内CAR-T和肿瘤早筛显示科研转化加速。生活健康端，夏季饮食、久坐办公和儿童健康持续引发焦虑式传播，真正值得关注的是高温季节风险管理、慢病预防和科学就医边界。","2026-06-15","https:\u002F\u002Fr2-tgmeng.tgmeng.com\u002Ftgmeng-news\u002F1(15).jpg",[164,165,166,167,168],"创新药出海","减重药","基因编辑","肿瘤早筛","健康科普",36291,324,{"id":172,"title":173,"summary":174,"category":52,"categoryName":53,"publishDate":175,"coverImage":176,"concepts":177,"aiPlatform":136,"aiModel":137,"model":137,"provider":138,"tokenUsage":182,"readMinutes":107,"heat":183,"markdown":90},3757,"GLP-1减重药数据密集发布，国产创新药研发加速突围","今日健康领域焦点集中在GLP-1\u002FGIP减重疗法的新进展，礼来与国产药企的临床数据与申报动态引发广泛关注。同时，中国学者在Cell等顶刊发表多项癌症与代谢疾病机制研究成果，CAR-T与ADC疗法亦取得突破性进展。资本市场方面，多家药企IPO进程推进，行业呈现科研与商业双轮驱动态势。","2026-06-14","https:\u002F\u002Fr2-tgmeng.tgmeng.com\u002Ftgmeng-news\u002F1(42).jpg",[98,178,179,180,181],"创新药研发","顶刊科研突破","CART与ADC","医药资本动态",17852,245,{"id":185,"title":186,"summary":187,"category":52,"categoryName":53,"publishDate":188,"coverImage":189,"concepts":190,"aiPlatform":138,"aiModel":194,"model":194,"provider":138,"tokenUsage":195,"readMinutes":107,"heat":196,"markdown":90},3738,"顶会释放前沿疗效数据，合规风暴重塑医药出海逻辑","今日健康与生物医药领域呈现前沿技术爆发与行业秩序重塑的特征。国际顶会ASCO与EHA释放大量肿瘤及慢病突破性数据，减重药多维获益研究引人瞩目。硬科技资本狂潮联动AI制药，推动技术大规模商业化。然而，国内集采常态化与合规强监管促使CSO传统模式终结，地缘博弈加剧CXO出海挑战。大众健康层面，夏季高发即时健康风险与食品安全问题成为公众情绪的触发点。","2026-06-13","https:\u002F\u002Fr2-tgmeng.tgmeng.com\u002Ftgmeng-news\u002F1(204).jpg",[191,192,99,193],"前沿医学","合规监管","消费健康","astron-code-latest",14421,258,{"id":198,"title":199,"summary":200,"category":52,"categoryName":53,"publishDate":201,"coverImage":202,"concepts":203,"aiPlatform":120,"aiModel":104,"model":104,"provider":121,"tokenUsage":208,"readMinutes":140,"heat":209,"markdown":90},3719,"药企博弈与AI落地交织，减重药竞争进入深水区","今日健康领域热点呈现明显的产业纵深感。药明康德起诉美国国防部事件，将地缘政治博弈从被动应对推向主动法律维权，成为观察中国CXO企业海外风险应对的标志性案例。与此同时，AI制药领域出现实质性商业订单，技术从概念验证迈向价值变现。减重药赛道则进入多靶点、口服化的白热化竞争阶段。节日相关的食品安全科普构成了广泛的民生传播层。","2026-06-12","https:\u002F\u002Fr2-tgmeng.tgmeng.com\u002Ftgmeng-news\u002F1(51).jpg",[204,99,205,206,207],"药企出海","减重药竞争","食品安全","产业博弈",22824,378,{"id":211,"title":212,"summary":213,"category":52,"categoryName":53,"publishDate":214,"coverImage":215,"concepts":216,"aiPlatform":220,"aiModel":221,"model":221,"provider":121,"tokenUsage":222,"readMinutes":88,"heat":223,"markdown":90},3700,"创新药密集收获，细胞治疗与减重市场争夺战升温","国内创新药研发迎来爆发期，多款重磅药物集中获批；细胞与基因治疗领域突破频现，但产业化与监管挑战并存；减重药市场从双雄争霸走向多方混战，国产力量加速布局；基础研究持续产出高水平成果，为未来竞争蓄力；同时，健康科普需求旺盛与资本活跃信号共同勾勒出行业的高热度图景。","2026-06-11","https:\u002F\u002Fr2-tgmeng.tgmeng.com\u002Ftgmeng-news\u002F1(36).jpg",[149,217,218,168,219],"细胞治疗","减重市场","产业资本","token-plan-cn.xiaomimimo.com","mimo-v2.5-pro",8835,352,18]